Literature DB >> 8579110

Hypoxic tumor cell death and modulation of endothelial adhesion molecules in the regression of granulocyte colony-stimulating factor-transduced tumors.

M P Colombo1, L Lombardi, C Melani, M Parenza, C Baroni, L Ruco, A Stoppacciaro.   

Abstract

C-26 colon adenocarcinoma cells transduced with the granulocyte colony-stimulating factor (G-CSF) gene form large tumors when injected into sublethally irradiated mice. These tumors regress when leukocyte function is reconstituted. Electron microscopy and immunocytochemical analysis of regressing C-26/G-CSF nodules indicates that tumor destruction is due mainly to hypoxia resulting from the functional loss of tumor vasculature and is only marginally due to direct cytolysis. Desegregation of basal lamina, cell swelling, and loss of junctions characterized the vessels within regressing tumors. Tumor cells were necrotic or filled with lipid vacuoles regardless of the distance from nearby vessels. Damage of tumor vasculature was dependent on the infiltrating leukocytes and the cytotoxic cytokines they produced. Locally produced interleukin-1 and tumor necrosis factor-alpha (TNF-alpha) induced vascular cellular adhesion molecule-1 (VCAM-1) and E-selectin on tumor vessels. Treatment with monoclonal antibodies to interferon-gamma (IFN-gamma) or TNF-alpha blocked tumor regression by inhibiting VCAM-1 and E-selectin expression on tumor-associated endothelial cells resulting in a reduced number of infiltrating leukocytes. Thus, C-26/G-CSF tumor regression presents features typical of hemorrhagic necrosis that occurs through the cytokines produced by infiltrating leukocytes in response to G-CSF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8579110      PMCID: PMC1861698     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  20 in total

1.  Immune interferon enhances functional properties of human granulocytes: role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor.

Authors:  B Perussia; M Kobayashi; M E Rossi; I Anegon; G Trinchieri
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

2.  Murine interleukin-4 displays potent anti-tumor activity in vivo.

Authors:  R I Tepper; P K Pattengale; P Leder
Journal:  Cell       Date:  1989-05-05       Impact factor: 41.582

3.  Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.

Authors:  F Cavallo; M Giovarelli; A Gulino; A Vacca; A Stoppacciaro; A Modesti; G Forni
Journal:  J Immunol       Date:  1992-12-01       Impact factor: 5.422

4.  Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.

Authors:  F J Burrows; P E Thorpe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

5.  Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium.

Authors:  A Vecchi; C Garlanda; M G Lampugnani; M Resnati; C Matteucci; A Stoppacciaro; H Schnurch; W Risau; L Ruco; A Mantovani
Journal:  Eur J Cell Biol       Date:  1994-04       Impact factor: 4.492

6.  Tumor necrosis factor (TNF).

Authors:  L J Old
Journal:  Science       Date:  1985-11-08       Impact factor: 47.728

7.  Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA.

Authors:  S J Russell; S A Eccles; C L Flemming; C A Johnson; M K Collins
Journal:  Int J Cancer       Date:  1991-01-21       Impact factor: 7.396

8.  Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology.

Authors:  G G MacPherson; R J North
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

9.  Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation.

Authors:  W F Westlin; M A Gimbrone
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

10.  The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity.

Authors:  M J Berendt; R J North; D P Kirstein
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

View more
  4 in total

Review 1.  Immunotherapy I: Cyclosine gene transfer strategies.

Authors:  M P Colombo; G Forni
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

2.  The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci.

Authors:  Sally A DuPré; Doug Redelman; Kenneth W Hunter
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

Review 3.  A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.

Authors:  Gizem Duru; Marjolein van Egmond; Niels Heemskerk
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

4.  Evolution of proliferation and the angiogenic switch in tumors with high clonal diversity.

Authors:  Scott T Bickel; Joseph D Juliano; John D Nagy
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.